Vaxxinity (VAXX) News Today → $21,000 in profits in six weeks? (From InvestorPlace) (Ad) Free VAXX Stock Alerts $0.11 -0.02 (-15.26%) (As of 05/8/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineWhy Is Vaxxinity (VAXX) Stock Up 39% Today?investorplace.com - May 3 at 8:24 AMVaxxinity (NASDAQ:VAXX) Shares Down 6.6% americanbankingnews.com - May 2 at 3:24 AMWhy Is Vaxxinity (VAXX) Stock Down 58% Today?investorplace.com - April 22 at 8:40 AMVaxxinity Plans to Delist Shares From Nasdaqmarketwatch.com - April 19 at 7:30 PMVaxxinity Issues Shareholder Letterglobenewswire.com - April 19 at 6:53 PMVaxxinity Announces Intention to Voluntarily Delist and Deregister its Class A Common Stockglobenewswire.com - April 19 at 4:27 PMVaxxinity to Present Clinical Data at the Annual Academy of Neurology 2024 Annual Meetingglobenewswire.com - March 28 at 9:23 AMVAXX Stock Earnings: Vaxxinity Beats EPS for Q4 2023investorplace.com - March 27 at 11:03 PMVaxxinity Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Corporate Updatesglobenewswire.com - March 27 at 4:41 PMVaxxinity Announces Positive Target Engagement Data from Phase 1 Clinical Trial for Parkinson's Disease at AD/PD™ 2024globenewswire.com - March 7 at 10:32 AMVaxxinity’s Heart Health Innovation to Reduce LDL Cholesterol Levelsfinance.yahoo.com - February 15 at 2:41 PMVaxxinity’s Cholesterol Vaccine Candidate Successfully Lowers LDL-C: Preclinical Data Publishedfinance.yahoo.com - February 15 at 9:40 AMVaxxinity's Cholesterol Vaccine Candidate Successfully Lowers LDL-C: Preclinical Data Publishedglobenewswire.com - February 15 at 8:00 AMVaxxinity to Present Clinical and Preclinical Pipeline Data at AD/PD 2024finance.yahoo.com - February 13 at 8:20 AMVaxxinity (NASDAQ:VAXX) Shares Down 2.2% marketbeat.com - February 8 at 2:46 AMVaxxinity, UF Join Forces Against Neurodegenerative Diseasesfinance.yahoo.com - January 30 at 2:16 PMVaxxinity Announces Research Collaboration on Active Immunotherapies for Neurodegenerative Diseases with University of Floridafinance.yahoo.com - January 30 at 9:15 AMVaxxinity & UCF to Collaborate on Space Medicine Researchfinance.yahoo.com - January 19 at 3:05 PMVaxxinity Announces Collaboration on Space Medicine Research with University of Central Floridafinance.yahoo.com - January 18 at 8:33 AMVaxxinity to Present at the 2024 J.P. Morgan Healthcare Conferencefinance.yahoo.com - January 3 at 12:34 PMThe Zacks Analyst Blog Highlights Biogen, Prothena, AC Immune's and Vaxxinityfinance.yahoo.com - December 12 at 11:22 AMAlzheimer's Disease Vaccines: Promising Developments, Renewed Enthusiasm From Biogen, Eli Lilly And Othersmarkets.businessinsider.com - November 21 at 7:47 PMSeveral Alzheimer's vaccines enter clinical trials amid breakthrough treatments' successfoxnews.com - November 20 at 6:32 PMResearchers return to Alzheimer's vaccines, buoyed by recent drug successmsn.com - November 20 at 8:31 AMVaxxinity to Present at Upcoming November Medical and Investor Conferencesfinance.yahoo.com - November 13 at 7:50 PMVaxxinity Reports Third Quarter 2023 Financial Results and Provides Corporate Updatefinance.yahoo.com - November 8 at 9:19 AMPrivate companies invested in Vaxxinity, Inc. (NASDAQ:VAXX) copped the brunt of last week's US$41m market cap declinefinance.yahoo.com - October 10 at 4:04 PMMovers Lab Fund I. Lp Prime Sells 25,089 Shares of Vaxxinity, Inc. (NASDAQ:VAXX) Stockmarketbeat.com - September 8 at 8:27 PMDown -22.18% in 4 Weeks, Here's Why You Should You Buy the Dip in Vaxxinity, Inc. (VAXX)finance.yahoo.com - September 7 at 3:46 PMVaxxinity Says UB-311 Shows Potential Advancements in Alzheimer’s Treatmentfinance.yahoo.com - August 11 at 3:01 AMVaxxinity Announces Publication of UB-311 Safety, Tolerability, Immunogenicity, and Clinical Efficacy Data from Phase 2a Trial in Alzheimer’s Diseasefinance.yahoo.com - August 10 at 10:36 AMVaxxinity Reports Second Quarter 2023 Financial Results and Provides Corporate Updatefinance.yahoo.com - August 9 at 1:09 PMVaxxinity Appoints Peter Powchik, M.D., to Executive Vice President, Global Scientific Directorfinance.yahoo.com - July 28 at 10:57 AMVaxxinity Appoints Dr. Peter Powchik as Global Scientific Directorfinance.yahoo.com - July 28 at 10:57 AMLincoln National Corp Invests $93,000 in Vaxxinity, Inc. (NASDAQ:VAXX)marketbeat.com - July 28 at 5:56 AMPromising Milestone in Neurodegenerative Disease Treatment: Vaxxinity’s UB-312 in Parkinson’s Patientsfinance.yahoo.com - July 17 at 3:23 PMVaxxinity Demonstrates Target Engagement of Toxic Alpha-Synuclein in Parkinson’s Patientsfinance.yahoo.com - July 17 at 10:21 AMMcAdam LLC Buys New Stake in Vaxxinity, Inc. (NASDAQ:VAXX)marketbeat.com - July 9 at 6:38 AMPositive Phase 1 Results: Vaxxinity’s UB-312 Shows Promise in Parkinson’s Diseasefinance.yahoo.com - June 22 at 3:17 PMVaxxinity Touts Encouraging Data From Early-Stage Parkinson's Vaccine Trialfinance.yahoo.com - June 22 at 3:17 PMVaxxinity Announces UB-312 Successfully Met Primary Objectives of Phase 1 Clinical Trial in Parkinson’s Diseasefinance.yahoo.com - June 22 at 10:16 AMVaxxinity Reports First Quarter 2023 Financial Results and Provides Corporate Updatefinance.yahoo.com - May 9 at 9:26 AMVaxxinity, Inc.'s (NASDAQ:VAXX) biggest owners are private companies who got richer after stock soared 23% last weekfinance.yahoo.com - May 3 at 8:26 AMWeekly Biotech Pulse: Vaxxinity results, Biogen's FDA review, and more | Pro Recapfinance.yahoo.com - April 24 at 8:42 AMVaxxinity to Present at World Vaccine Congress, American Academy of Neurology, and BNA2023 Festival of Neuroscience in Aprilfinance.yahoo.com - March 28 at 12:42 PMVaxxinity Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Corporate Updatesfinance.yahoo.com - March 27 at 10:49 AMVaxxinity Joins TransCelerate Research and Development Consortiumfinance.yahoo.com - March 21 at 10:17 AMVaxxinity Announces First Subjects Dosed in Phase 1 Clinical Trial of VXX-401, Investigational Anti-PCSK9 Vaccine to Treat Hypercholesterolemiafinance.yahoo.com - March 20 at 8:07 AMVaxxinity to Present at Upcoming March Scientific and Medical Conferencesfinance.yahoo.com - March 2 at 9:54 AMNektar Therapeutics (NKTR) was downgraded to a Sell Rating at Jefferiesmarkets.businessinsider.com - February 24 at 5:39 PM Get Vaxxinity News Delivered to You Automatically Sign up to receive the latest news and ratings for VAXX and its competitors with MarketBeat's FREE daily newsletter. Email Address READ THIS – If You Missed Out On The AI Boom (Ad)Adam’s research shows a radical new technology is set to grow 10X faster than the internet … and drastically alter manufacturing, healthcare, agriculture … even energy. Nvidia’s CEO said it will be, “flat out, the biggest [tech] revolution ever.” Click on Adam's shiny forehead for more details. VAXX Media Mentions By Week VAXX Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. VAXX News Sentiment▼0.840.36▲Average Medical News Sentiment VAXX News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. VAXX Articles This Week▼20▲VAXX Articles Average Week Get Vaxxinity News Delivered to You Automatically Sign up to receive the latest news and ratings for VAXX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Talphera News Today Tonix Pharmaceuticals News Today Aytu BioPharma News Today VBI Vaccines News Today Cocrystal Pharma News Today Minerva Neurosciences News Today Vincerx Pharma News Today Indaptus Therapeutics News Today NeuroSense Therapeutics News Today Orgenesis News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:VAXX) was last updated on 5/8/2024 by MarketBeat.com Staff From Our PartnersThe #1 Biotech Stock to Watch in 2024 is Attacking Viruses in a Unique WaySmallcaps DailyTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaAI “wealth window” is closing June 25thParadigm PressThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldGold Set to EXPLODE!Gold Safe ExchangeCharles Payne Demystifies OptionsUnstoppable ProsperityWatch this FREE trading tutorial while it’s still availableInvestorPlaceShocking: One AI startup's revenue could surge 4,735%Manward Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vaxxinity, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
